{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:53:01Z","timestamp":1790635981102,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"European Union TheraVac Demonstration project","award":["QLK2-CT-2002-01299;"],"award-info":[{"award-number":["QLK2-CT-2002-01299;"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Immunol"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p>We report the results of the Theravac\u201001 phase I trial, which was conducted to evaluate the safety and immunogenicity of a poxvirus\u2010based vector, <jats:styled-content style=\"fixed-case\">NYVAC<\/jats:styled-content>, expressing Gag, Pol, Nef, and Env from an <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> clade B isolate. <jats:styled-content style=\"fixed-case\">NYVAC<\/jats:styled-content>\u2010B vaccine was injected intra\u2010muscularly into ten <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients successfully treated with antiretroviral therapy, twice on day 0 and again at week 4. Safety and immunogenicity were monitored for 48 weeks. <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010specific <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses following immunization were quantitatively analyzed using an <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010\u03b3 <jats:styled-content style=\"fixed-case\">ELISPOT<\/jats:styled-content> assay and qualitatively characterized for their functional profile (including multiple cytokines secretion plus cytotoxic and proliferation capacity) by polychromatic flow cytometry. Our results indicate that the <jats:styled-content style=\"fixed-case\">NYVAC<\/jats:styled-content>\u2010B vaccine is safe and highly immunogenic, as indicated by increased <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010specific <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses in virtually all vaccinees. Interestingly, both an expansion of preexisting <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses, and the appearance of newly detected <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010specific <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4<jats:sup>+<\/jats:sup> and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>8<jats:sup>+<\/jats:sup> <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses were observed. Furthermore, immunization mostly induced an increase in Gag\u2010specific <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses. In conclusion, <jats:styled-content style=\"fixed-case\">NYVAC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> immunization induces broad, vigorous, and polyfunctional <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010specific <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010cell responses, suggesting that poxvirus\u2010based vaccine regimens may be instrumental in the therapeutic <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> vaccine field.<\/jats:p>","DOI":"10.1002\/eji.201242696","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T16:51:41Z","timestamp":1346172701000},"page":"3038-3048","source":"Crossref","is-referenced-by-count":30,"title":["NYVAC immunization induces polyfunctional HIV\u2010specific T\u2010cell responses in chronically\u2010infected, ART\u2010treated HIV patients"],"prefix":"10.1002","volume":"42","author":[{"given":"Alexandre","family":"Harari","sequence":"first","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"},{"name":"Swiss Vaccine Research Institute Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Rozot","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas Bellutti","family":"Enders","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Vigano","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Tapia","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Castro","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Burnet","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Global Health Academic Medicial Center Amsterdam Institute for Global Health and Development University of Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Moog","sequence":"additional","affiliation":[{"name":"INSERM Unit 748 Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Garin","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie IRBA Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"UPMC Universit\u00e9 de Paris 06 and INSERM UMRS 943 Paris France"},{"name":"Cellular Immunology Laboratory Pierre and Marie Curie University INSERM UMRS 543, Piti\u00e9\u2010Salp\u00eatri\u00e8re Hospital Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Autran","sequence":"additional","affiliation":[{"name":"Cellular Immunology Laboratory Pierre and Marie Curie University INSERM UMRS 543, Piti\u00e9\u2010Salp\u00eatri\u00e8re Hospital Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"},{"name":"Swiss Vaccine Research Institute Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Alexandre","family":"Bart","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy Lausanne University Hospital Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a239"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV\u2010infected adults with a CD4 cell count greater than 500 cells\/mm3 on long\u2010term combination antiretroviral therapy reach same mortality rates as the general population","volume":"46","author":"Lewden C.","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15109"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202372199"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.221452198"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5493.946"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.122"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/80481"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328344cea5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1100600"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000206504.09159.d3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/315860"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.010"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/432002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.03.040"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0047"},{"key":"e_1_2_7_20_1","first-page":"279","article-title":"Immunological and virological efficacy of a therapeutic immunization combined with interleukin\u20102 in chronically HIV\u20101 infected patients","volume":"19","author":"Levy Y.","year":"2005","journal-title":"AIDS"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","unstructured":"Casazza J. Bowman K. Ambrozak D. Gordon I. Roederer M. Enama M. Nason M.et\u00a0al. IncreasedHIV\u2010specific immunity inHIV\u2010infected individuals vaccinated with aDNAprime rAd5 boost regimenCROI2010.","DOI":"10.1186\/1742-4690-6-S3-P315"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq143"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fdce94"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340fe55"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502393102"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4818"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1520"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.03.050"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02528-08"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.COH.0000232343.23533.70"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3282fbaa81"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni845"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.20.10900-10909.2003"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031598"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/650492"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis379"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00437-12"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00138-10"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834cdaba"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31818cde21"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032083"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.07.005"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.090"},{"key":"e_1_2_7_46_1","first-page":"3","article-title":"Optimal CTL epitope identification in HIV clade B and non\u2010clade B infection","author":"Frahm N.","year":"2005","journal-title":"HIV Mol. Immunol."},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00535-X"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071331"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02565-09"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21015"}],"container-title":["European Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Feji.201242696","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/eji.201242696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:14:42Z","timestamp":1696587282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/eji.201242696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/eji.201242696"],"URL":"https:\/\/doi.org\/10.1002\/eji.201242696","archive":["Portico"],"relation":{},"ISSN":["0014-2980","1521-4141"],"issn-type":[{"value":"0014-2980","type":"print"},{"value":"1521-4141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}